

Delic Launches Industry's First Family Support & Education Program at Ketamine Wellness Centers (KWC) Nationwide For Patient Community



Nation's Largest Chain of Ketamine Wellness Clinics Introduces First-of-Its-Kind Virtual Programming to Help Patients' Loved

Ones Prepare for Life After Ketamine Infusion Experience

VANCOUVER, BRITISH COLUMBIA - Nov 18, 2021 - Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today introduced its Family Support & Education program at Ketamine Wellness Centers (KWC), the largest chain of wellness centers providing ketamine treatments in the U.S. KWC was recently acquired by Delic and operates 10 ketamine infusion treatment clinics across eight states that have delivered more than 60,000 treatments to date across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas and Washington.

KWC's Family Support & Education program is a unique, free program specifically designed by medical professionals to help families, significant others and loved ones meaningfully support patients that have chosen to pursue ketamine infusion treatments. While ketamine represents a new class of medicines that have revolutionized therapies to treat depression, its rapid effects and benefits can quickly change family and relationship dynamics. KWC's virtual Family Support & Education sessions will address pertinent topics, including what friends and family can expect from the process, roles they can take to support the patient during treatment, and how they can prepare for the rapid positive changes in their loved ones' lives.

Each hour-long session will be led by Kevin Nicholson, CEO of KWC and Chief Operating Officer for Delic, who has over 20 years of clinical and healthcare management experience. In addition to providing patients' families with resources and actionable guidance, the program also allows participants to connect in a safe, supportive and community-centered environment.

"After delivering over 60,000 treatments across the country, our team recognized a distinct demand from patients' loved ones to better understand and support the holistic impacts of ketamine infusion therapy and how they can support the healing," said Nicholson. "The long-term success of these treatments often depends on the quality of patients' surrounding environments once they leave our clinics. We look forward to equipping our patients' support circles with the necessary tools and resources to ensure their overall health and wellness."

"Delic is proud to offer this free and vital service to help our patient communities across the U.S. receive the support they need during this challenging period of their lives," said Matt Stang, co-founder and CEO of Delic. "Since 2015 KWC has been a leader in providing personalized, effective and affordable mental health treatments for conditions such as major depression, anxiety and PTSD, and this initiative is another example of doing the right thing and leading by example. We are confident that Kevin's team will guide these families through this journey with the same attention and care they provide all their patients through the Family Support & Education program."

KWC's national network of clinics adds to Delic's existing portfolio of two clinics operated by Ketamine Infusion Centers LLC ("KIC") in California and Arizona, cementing its position as the leading and largest wellness provider in the country. Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from new medicines and treatments for a variety of mental health conditions and adds to their position as a

central hub of education, media, and cultural conversations around these new medicines and treatments. With a recent successful private placement of CAD\$7MM, Delic is actively scouting new locations in cities with a growing patient base.

About Ketamine Wellness Centers

Ketamine Wellness Centers (KWC) is the largest ketamine therapy provider in the United States with 10 clinic locations serving communities across eight states. Since 2011 KWC has been a trusted leader in bringing IV ketamine therapy into mainstream health care. KWC has provided over 60,000 treatments to clinically eligible patients, from young adults to seniors, in addition to developing specialized programs for veterans and first responders. The KWC team, including a core group of physicians, psychologists, clinicians, and executives, is dedicated to providing value-based, personalized, clinically controlled ketamine infusion care for people suffering from treatment-resistant depression, anxiety, PTSD, OCD and chronic pain. KWC's scalable business and treatment model is designed for further rapid expansion along with breakthrough innovations in effective therapies and services.

About Delic Corp

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information and Statements

This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction; anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the

COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; the ability of the parties to obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of other conditions to the consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the Transaction.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

Investor Relations Contact Rich Rodriguez Delic Corp rich@deliccorp.com Media Contact

MATTIO Communications

delic@mattio.com

Noah Bethke



Contact us for more information.

invest@deliccorp.com

(708) 515-4925

AS SEEN IN CAREERS

DISCLAIMER

PRIVACY POLICY